Rapid Anticoagulation Prevents Ischemic Damage "RAPID"

Completed

Phase N/A Results

Eligibility Criteria

Inclusion Criteria

Patients who present within 12 hours of non-lacunar ischemic stroke, who have a baseline National Institute of Health Stroke Scale (NIHSS) level of consciousness =< 1 and a global NIHSS score > 6, will be eligible for this trial.

Exclusion Criteria

Patients with CT evidence of bleeding, who have any stroke syndrome that could be explained by a lacunar infarct, who have a premorbid modified Rankin score (MRS) > 2 , rapidly improving symptoms, any known coagulopathy, a history of severe trauma, pulmonary embolism, acute myocardial infarction, deep venous thrombosis, or ischemic stroke within 3 months of enrollment, who have any history of hemorrhagic stroke, who present with hemiplegia, fixed eye, and/or head deviation, who have seizures associated with stroke onset, who have a history of major surgery within the previous 14 days, gastrointestinal or urinary tract hemorrhage within the past year, arterial puncture, complicated venous puncture or anticoagulant use within the previous 7 days, who are severely hypertensive at baseline (systolic > 200 ; diastolic > 110), who have received thrombolytics for the current stroke episode, who have an intracranial neoplasm, arteriovenous malformation, or presumed septic embolus, who have a baseline blood glucose < 50 mg/dL or > 400 g/dL, a baseline platelet count < 100,000/mm3, or a hematocrit < 25, who have hemorrhagic retinopathy, CT-evidenced severe leukoaraiosis, a known allergy to aspirin, any serious or terminal comorbid illness, or who are participating in another clinical trial, will be excluded from this study.